News Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Market Closed - Warsaw S.E. Other stock markets 09:25:46 29/04/2024 pm IST			5-day change	1st Jan Change
48.85 ^PLN	-0.91%		-4.22%	-15.04%

13/03	Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/03	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	06/03	CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	14/02	CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	31/01	CI
Transcript : Ryvu Therapeutics S.A. - Special Call	11/12
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	07/12	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Ryvu Therapeutics - Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes	23/23/23	AQ
Transcript : Ryvu Therapeutics S.A. - Special Call	23/23/23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23/23/23	CI
Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	17/23/17	AQ
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
Ryvu and TIM to enter Warsaw's mWIG40 index	31/23/31	RE
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	11/22/11	CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	30/22/30	MT
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	30/22/30	MT
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	30/22/30	CI
Ryvu Therapeutics S.A. announced that it expects to receive ?20 million in funding from BioNTech SE	30/22/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Summary

Filters